Azoles induce reactive oxygen species in Mycobacterium tuberculosis which is not associated with cell death. 2017. H.A. Howell Wescott, D.M. Roberts, C.L. Allebach, R. Kokoczka and T. Parish. ACS Omega.2: 41-51.
Current challenges in drug discovery for tuberculosis. 2017. A. Kumar, S. Chettiar, and T. Parish Expert Opin Drug Discov.12: 1-4.
A target-based whole cell screen approach to identify inhibitors of Mycobacterium tuberculosis signal peptidase. S.A. Bonnett, J. Ollinger, S. Chandrasekera, S. Florio, T. O’Malley, M. Files, J. Jee, J. Ahn, A. Casey, Y. Ovechkina, D. Roberts, A. Korkegian, T. Parish* ACS Inf Dis. 2: 893-902.
Oxadiazoles have butyrate-specific conditional activity against Mycobacterium tuberculosis. 2016. J. Early, A. Casey, M.A. Martinez-Grau, I.C.G. Valcarcel, M. Vieth, J. Ollinger, M.A. Bailey, T. Alling, M. Files, Y. Ovechkina, and T. Parish. Antimicrob. Ag. Chemother. 60: 3608-3616
Synthesis and evaluation of the 2-aminothiazoles as anti-tubercular agents. 2016. E.A. Kesicki, M.A. Bailey, Y. Ovechkina, J.V. Early, T. Alling, J. Bowman, E.S. Zuniga, S. Dalai, N. Kumar, T. Masquelin, P.A. Hipskind, J. Odingo and T. Parish. PLOS One. 11(5): e0155209
Identification of phenoxyalkylbenzimidazoles with anti-tubercular activity. 2015. N.S. Chandrasekera, T. Alling, M.A. Bailey, M. Files, J.V. Early, J. Ollinger, Y. Ovechkina, T. Masquelin, P.V. Desai, J.W. Cramer, P.A. Hipskind, J.O. Odingo, and T. Parish. J. Med Chem. 58(18):7273-7285.
Optimization and evaluation of 5-styryl-2-oxathiazol-2-one Mycobacterium tuberculosis proteasome inhibitors as potential anti-tubercular agents. 2015. F. Russo, J. Gising, L. Akerbladh, A. Roos, A. Naworyta, S. Mowbray, A. Sokolowski, I. Hendersson, T. Alling, N. Bailey, M. Files, T. Parish, A. Karlen and M. Larhed. Chemistry Open. 4: 342 –362.